Wall Street analysts expect ADMA Biologics Inc (NASDAQ:ADMA) to announce $6.68 million in sales for the current quarter, according to Zacks Investment Research. Two analysts have provided estimates for ADMA Biologics’ earnings, with estimates ranging from $5.50 million to $7.85 million. ADMA Biologics reported sales of $3.33 million during the same quarter last year, which indicates a positive year over year growth rate of 100.6%. The firm is scheduled to announce its next quarterly earnings results on Friday, February 23rd.

On average, analysts expect that ADMA Biologics will report full-year sales of $6.68 million for the current fiscal year, with estimates ranging from $16.30 million to $18.61 million. For the next financial year, analysts forecast that the business will report sales of $38.15 million per share, with estimates ranging from $28.31 million to $48.00 million. Zacks Investment Research’s sales calculations are an average based on a survey of research firms that that provide coverage for ADMA Biologics.

Several brokerages have issued reports on ADMA. ValuEngine cut ADMA Biologics from a “sell” rating to a “strong sell” rating in a research report on Friday, September 1st. Raymond James Financial raised ADMA Biologics from a “market perform” rating to an “outperform” rating and set a $5.00 target price on the stock in a research report on Tuesday, November 14th.

In other news, Director Eric I. Richman bought 25,000 shares of the company’s stock in a transaction on Thursday, November 9th. The shares were acquired at an average cost of $2.15 per share, with a total value of $53,750.00. Following the completion of the transaction, the director now owns 31,300 shares of the company’s stock, valued at approximately $67,295. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Adam S. Grossman acquired 485,000 shares of the stock in a transaction dated Thursday, November 9th. The shares were bought at an average cost of $2.15 per share, for a total transaction of $1,042,750.00. The disclosure for this purchase can be found here. Insiders acquired 526,500 shares of company stock worth $1,131,975 over the last three months. Insiders own 60.44% of the company’s stock.

A hedge fund recently raised its stake in ADMA Biologics stock. Iguana Healthcare Management LLC grew its stake in shares of ADMA Biologics Inc (NASDAQ:ADMA) by 276.7% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 565,000 shares of the biotechnology company’s stock after buying an additional 415,000 shares during the period. Iguana Healthcare Management LLC owned 2.19% of ADMA Biologics worth $1,740,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 32.78% of the company’s stock.

ADMA Biologics (ADMA) opened at $2.77 on Tuesday. The company has a quick ratio of 1.35, a current ratio of 2.36 and a debt-to-equity ratio of 2.26. ADMA Biologics has a 12-month low of $2.01 and a 12-month high of $5.80.

COPYRIGHT VIOLATION NOTICE: “ADMA Biologics Inc (ADMA) Expected to Post Quarterly Sales of $6.68 Million” was originally published by American Banking News and is the property of of American Banking News. If you are viewing this news story on another site, it was illegally copied and republished in violation of US & international copyright and trademark laws. The original version of this news story can be viewed at https://www.americanbankingnews.com/2017/12/05/adma-biologics-inc-adma-expected-to-post-quarterly-sales-of-6-68-million.html.

About ADMA Biologics

ADMA Biologics, Inc is a late-stage biopharmaceutical company that develops, manufactures and intends to market specialty plasma-based biologics for the treatment and prevention of infectious diseases. The Company is engaged in the development and commercialization of human plasma and plasma-derived therapeutics.

Get a free copy of the Zacks research report on ADMA Biologics (ADMA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for ADMA Biologics (NASDAQ:ADMA)

Receive News & Ratings for ADMA Biologics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ADMA Biologics Inc and related companies with MarketBeat.com's FREE daily email newsletter.